Antidiabetic agents and mortality risk, durability of immunity against reinfection, navigating from SARS-CoV-2 elimination to endemicity

Peer reviewed journals featured:

- Systematic reviews on:
  - Mortality risk associated with antidiabetic agents for type 2 diabetes and COVID-19 [here](#)
  - Seropositivity and safety of COVID-19 vaccines in cancer patients [here](#)
- A randomised controlled trial on airway pressure release ventilation in COVID-19 patients with acute respiratory failure [here](#)
- A narrative review on the durability of immunity against reinfection by SARS-CoV-2 [here](#)
- Modelling studies on:
  - Simulated surveillance testing and quarantine in vaccinated university students [here](#)
  - Machine learning for early prediction of adverse outcomes for COVID-19 patients [here](#)
- Observational studies on:
  - Communication strategies for mitigating COVID-19 vaccine-specific hesitancy [here](#)
  - Comirnaty (Pfizer) vaccine-induced responses in systemic lupus erythematosus [here](#)
  - Performance of seven SARS-CoV-2 self-tests [here](#)
  - Association of children’s physical activity and screen time with mental health during COVID-19 [here](#)
  - COVID-19 vaccine decision-making factors in racial and ethnic minority communities in Los Angeles [here](#) and associated commentary [here](#)
  - Effectiveness of Comirnaty (Pfizer) vaccine up to 6 months in the US [here](#)
- An editorial on mass testing of university students for COVID-19 [here](#)
- Commentary on:
  - Navigating from SARS-CoV-2 elimination to endemicity in Australia, Hong Kong, New Zealand, and Singapore [here](#)
  - COVID-19’s impact on evidence-based medicine [here](#)

Letters and correspondence discussed:

- Update on remdesivir for adults with COVID-19 [here](#)
- Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients [here](#)
The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Pre-peer review articles featured:
- An evaluation of the diagnostic accuracy of COVID-19 antigen tests [here](#).
- A randomised controlled trial of alteplase for respiratory failure in SARS-CoV-2 in COVID-19 (STARS) [here](#).
- Real-world safety data for the Comirnaty (Pfizer) vaccine [here](#).

Guidance and reports
- The World Health Organization published:
  - Its latest operational report on COVID-19 [here](#) and COVID-19 vaccine tracker [here](#).
  - A report on community centred approaches to health emergencies [here](#).
- A summary of the UK’s National Institute for Health and Care Excellence (NICE) guidance on vaccine-induced immune thrombocytopenia and thrombosis [here](#).
- TGA advice on COVID-19 vaccines not registered in Australia but in current international use [here](#).

News and blogs
- Complaints about UK politicians’ use of statistics rise sharply [here](#).
- A new WHO Hub for Pandemic and Epidemic Intelligence [here](#).
- Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk [here](#).
- Lancet investigation into origin of pandemic shuts down over bias risk [here](#).
- Vaccinating against COVID-19 and flu at same time is safe [here](#).

Click [here](#) to subscribe to the daily evidence digest.

Living Evidence Tables
Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on COVID-19 transmission, SARS-CoV-2 vaccines, and variants of concern, post-acute sequelae of COVID-19 (PASC), surgery and COVID-19, rapid testing and risk mitigation strategies.